| Disease | IN THIS STUDY, THE SERORUM TROCHOSANTHIN ANTIBIODY WAS ASSAYED AND A SKIN TEST WAS DONE FOR 103 CASES 1-4 YEARS AFTER THEIR TRICHOSANTHIN TERMINATED MID-PREGNANCY, AND IN ORDER TO PRESENT A STRIKING CONTRAST, THE SAME ASSAY TESTS WAS DONE FOR
ANOTHER 103 PREGNANT WOMEN WHO HAD NEVER RECEIVED TRICHOSANTHIN BEFORE. NO SHARP DISTINCTON WAS MADE WHEN MICRO-INDIRECT HEMOAGGLUTINATION METHOD WAS USED FOR THE ASSAY OF SERUM ANTIBODY WITH FORMALDEHYDE AND TANNIC ACID TREATED TRICHOSANTHIN
SENSITIZED SHEEP RBC USED AS ANTIGEN. RESULT: AMONG THE 103 CASES FOR STUDY: SKIN TEST "+" 27 CASES (26.21%), SERUM ANTIBODY "+" 24 CASES (23.33%). IN THE 103 CASES OF THE CONTROL GROUP, SKIN TEST '+" 2 CASES (1.94%), SERUM ANTIBODY "+" 9 CASES
(8/7%). P<0.01. THE PERCENTAGE OF CASES WITH POSITIVE SKIN TEST AND SERUM ANTIBODY WAS SIGNIFICANTLY HIGHER IN THE FOLLOW-UP GROUP THAN THE CONTROL GROUP. 2. AMONG THE 82 CASES: 1-7 YEARS AFTER TRICHOSANTHIN INDUCED ABORTION, 23 CASES (28.04%)
WERE SERUM ANTIBODY POSITIVE. AMONG ANOTHER 21 CASES; 8-14 YEARS AFTER ABORTION, ONLY 1 CASE (4.76%) WAS ANTIBODY POSITIVE. THIS INDICATED THAT TRICHOSANTHIN ANTIBODY WAS NOT A LIFE-LONG ANTIBODY. 3. AMONG THE 27 SKIN-TEST POSITIVE CASES, 14
WERE ANTIBODY PSOITIVE (51.85%); AND AMONG THE 75 SKIN-TEST NEGATIVE CASES, ONLY 10 WERE ANTIBODY POSITIVE (13.6%); AND AMONG THE 24 ANTIBODY POSITIVE CASES 14 WERE SKIN TEST POSITIVE (58.33%). THIS SHOWED THAT THERE WAS CLOSE INTERRELATIONSHIP
BETWEEN SKIN TEST AND SERUM ANTIBODY. POSITIVE SKIN TEST IN MOST CASES CAN REFLECT THE PRESENCE OF ANTIBODY IN THE SERUM. 4. THERE WAS NO SIGNIFICANT DIFFERNECE (P>0.05) IN THE PERCENTAGE OF SKIN TEST POSITIVE AND SERUM ANTIBODY POSITIVE CASES
BETWEEN THE GROUP OF INTRA-AMNIOTIC MEDICATION AND INTRAMUSCULAR MEDICATION. BASED ON THE AUTHOR'S MORE THAN 10 YEARS CLINICAL OBSERVATION AND THE RESULT OF THIS STUDY, IT IS CONSIDERED THAT THE SENSITIVITY OF THE PATIENT TO TRICHOSANTHIN AND
NOT ANTIBODY PLAYS A MAJOR ROLE IN THE ANAPHYLACTIC REACTION. THE IMPORTANCE AND INDISPENSABILITY OF THE SKIN TEST AND TRAIL DOSE BEFORE THE REGULAR MEDICATION IS EMPHASIZED. |